Decision: Favourable
Study Title:
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
NREC Code:
21-NREC-CT-014
Decision:
Favourable
Meeting Date:
07/07/2021
Study Type:
CT application
Principal Investigator:
Prof Ray McDermott
PI Institution:
Tallaght University Hospital
Sponsor:
Covance CAPS Ltd Authorised by Merck Sharp & Dohme Corp